Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago.
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top -and-bottom-line estimates for Alkermes (ALKS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Alkermes (ALKS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Alkermes (ALKS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Alkermes (ALKS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Alkermes (ALKS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
